Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MAP 315
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Bacthera
Deal Size : Inapplicable
Deal Type : Inapplicable
Microba Commences Phase I Clinical Trial for IBD Therapeutic
Details : MAP 315 is a live biotherapeutic product (LBP) consisting of lyophilised bacteria in an enteric coated capsule which is orally administered and being developed as an investigational product for the treatment of IBD and ulcerative colitis (UC).
Product Name : MAP 315
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
June 27, 2023
Lead Product(s) : MAP 315
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Bacthera
Deal Size : Inapplicable
Deal Type : Inapplicable
Microba Accelerates Cancer Program With New Leads
Details : Microba’s Cancer Immuno-Oncology Neoadjuvant Therapy is targeting discovery and development of a microbiome therapy to improve response rates in cancer patients receiving immune checkpoint inhibitor (ICI) therapy, with a specific focus on Melanoma and ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 05, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : Ginkgo Bioworks
Deal Size : Undisclosed
Deal Type : Partnership
Details : The collaboration aims to build on Microba’s precision approach to LBP development with an in-depth evaluation of the company’s strains using Ginkgo’s high throughput, automatedscreening capabilities.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
April 04, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : Ginkgo Bioworks
Deal Size : Undisclosed
Deal Type : Partnership